1R,3S,4S)-3-(6-溴-1H-苯并咪唑-2-基)-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯

中文名称(1R,3S,4S)-3-(6-溴-1H-苯并咪唑-2-基)-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯

中文同义词(1R,3S,4S)-3-(6-溴-1H-苯并咪唑-2-基)-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯;雷迪帕韦中间休2;(1R,3S,4S)-3-(6-溴-1H-苯并咪唑-2-基)-2-氮杂双环[2.2.1]庚烷-2-羧;(1R,3S,4S)-3-(6-溴-1H-苯并[D]咪唑基-2-基)-2-氮杂-双环[2,2,1]庚烷-2-甲酸叔丁酯;雷迪帕韦中间体51KG;雷迪帕韦中间体06;(1R,3S,4S)-3-(6-溴-1H-苯并咪唑-2-基)-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯(1R,3S,4S)-3-(6-BROMO-1H-BENZIMIDAZOL-2-YL)-2-AZABICYCLO[2.2.1]HEPTANE-2-CARBOXYLICACID1,1-DIMETHYLETHYLESTER;(1R,3S,4S)-3-(6-溴-1H-苯并咪唑-2-基)-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯1256387-74-2

英文名称2-Azabicyclo[2.2.1]heptane-2-carboxylicacid,3-(6-broMo-1H-benziMidazol-2-yl)-,1,1-diMethylethylester,(1R,3S,4S)-

英文同义词2-Azabicyclo[2.2.1]heptane-2-carboxylicacid,3-(6-broMo-1H-benziMidazol-2-yl)-,1,1-diMethylethylester,(1R,3S,4S)-;(1R,3S,4S)-3-(6-Bromo-1H-benzimidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylicacid1,1-dimethylethylester;(1R,3S,4S)-tert-butyl3-(6-broMo-1H-benzo[d]iMidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate;(1R,3S,4S)-tert-butyl3-(6-broMo-1Hbenzo[d]iMidazol-2-yl)-2-azabicyclo[2,2,1]heptanes-2-carboxylate;LedipasvirinterMediates;(1R,3S,4S)-3-(6-Bromo-1Hbenzimidazol-2-yl)-2-azabicyclo[2,2,1]heptane--2-carboxylicacid-1,1-dimethylethyleste;Ledipasvirsidechain2;tert-butyl(1R,3S,4S)-3-(6-bromo-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate

CAS号1256387-74-2

分子式C18H22BrN3O2

沸点554.3±30.0 °C(Predicted)

密度1.455±0.06 g/cm3(Predicted)

储存条件2-8°C

酸度系数(pKa)10.68±0.10(Predicted)

应用(1R,3S,4S)-3-(6-溴-1H-苯并咪唑-2-基)-2-氮杂双环[2.2.1]庚烷-2-羧酸叔丁酯可用作医药合成中间体，如制备新抗病毒NS5A抑Chemicalbook制剂Ledipasvir(GS5885)与NS5B阻断剂Sofosbuvir二联复方组合的Harvoni，是吉利德2013年12月获准的一个重磅丙肝治疗药物。